CoChat

A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics

Open access
Price, Lauren S. L., Stern, Stephan T., Deal, Allison M., Kabanov, Alexander V., Zamboni, William C. · 2020 · Science Advances

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Interpretation of nanoparticle PK results can be markedly influenced by differing PK metrics selected.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aay9249

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Comparisons between %ID in tumor and traditional PK metrics for all datasets (i.e., all types of nanoparticles). Correlation plots for all datasets between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) [ρ = 0.183 all data (AD); ρ = 0.151 excluding outliers (EO)] and a weak relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.319 AD; ρ = 0.289 EO). There was a moderate relationship between %ID in tumor and the tumor Cmax (ρ = 0.562 AD; ρ = 0.572 EO).
Fig. 1 Comparisons between %ID in tumor and traditional PK metrics for all datasets (i.e., all types of nanoparticles). Correlation plots for all datasets between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) [ρ = 0.183 all data (AD); ρ = 0.151 excluding outliers (EO)] and a weak relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.319 AD; ρ = 0.289 EO). There was a moderate relationship between %ID in tumor and the tumor Cmax (ρ = 0.562 AD; ρ = 0.572 EO).CC BY-NC · PubMed Central
Fig. 2 Comparisons between %ID in tumor and traditional PK metrics in the liposome subset. Correlation plots for the liposome subset between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all liposome datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) (ρ = 0.145 AD; ρ = 0.023 EO) and no relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.150 AD; ρ = 0.029 EO). There was a weak relationship between %ID in tumor and the tumor Cmax (ρ = 0.412 AD; ρ = 0.514 EO).
Fig. 2 Comparisons between %ID in tumor and traditional PK metrics in the liposome subset. Correlation plots for the liposome subset between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all liposome datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) (ρ = 0.145 AD; ρ = 0.023 EO) and no relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.150 AD; ρ = 0.029 EO). There was a weak relationship between %ID in tumor and the tumor Cmax (ρ = 0.412 AD; ρ = 0.514 EO).CC BY-NC · PubMed Central
Fig. 3 Comparisons between %ID in tumor and traditional PK metrics in the polymetric subset. Correlation plots for the polymeric subset between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all polymeric datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) (ρ = 0.094 AD; ρ = 0.097 EO) and a weak relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.422 AD; ρ = 0.447 EO). There was a moderate relationship between %ID in tumor and the tumor Cmax (ρ = 0.547 AD; ρ = 0.519 EO).
Fig. 3 Comparisons between %ID in tumor and traditional PK metrics in the polymetric subset. Correlation plots for the polymeric subset between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all polymeric datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) (ρ = 0.094 AD; ρ = 0.097 EO) and a weak relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.422 AD; ρ = 0.447 EO). There was a moderate relationship between %ID in tumor and the tumor Cmax (ρ = 0.547 AD; ρ = 0.519 EO).CC BY-NC · PubMed Central
Fig. 4 Comparisons between %ID in tumor and traditional PK metrics in the inorganic subset. Correlation plots for the inorganic subset between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all inorganic datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) (ρ = 0.265 AD; ρ = 0.243 EO) and a weak relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.322 AD). There was a moderate relationship between %ID in tumor and the tumor Cmax (ρ = 0.618 AD; ρ = 0.605 EO).
Fig. 4 Comparisons between %ID in tumor and traditional PK metrics in the inorganic subset. Correlation plots for the inorganic subset between %ID in tumor (per Wilhelm et al.) and AUCtumor/AUCblood ratio (%) (A), RDI-OT AUCtumor (B), and tumor Cmax (C). Plots are shown with all inorganic datasets (i, outliers shown as □) and with outliers excluded (ii). There was no relationship between %ID in tumor and AUCtumor/AUCblood ratio (%) (ρ = 0.265 AD; ρ = 0.243 EO) and a weak relationship between %ID in tumor and RDI-OT AUCtumor (ρ = 0.322 AD). There was a moderate relationship between %ID in tumor and the tumor Cmax (ρ = 0.618 AD; ρ = 0.605 EO).CC BY-NC · PubMed Central
Fig. 5 Example concentration versus time profiles of NPs in blood (left y axis) and tumor (right y axis) and PK metric calculation. The concentration versus time profile in blood is represented by the red symbols and lines. The concentration versus time profile in tumor is represented by the blue symbols and lines. The dotted red and blue lines represent the approximate variability in interquartile range for the blood and tumor concentration versus time profiles, respectively. The dashed gray line represents a constant tumor concentration of 3.5 %ID/g that yields the same AUCtumor (250 hours*%ID/g) as the actual tumor concentration versus time profile. The %ID in tumor calculated by Wilhelm et al. of 0.7% is the average %ID found in the tumor at every 1-hour interval throughout the entire PK evaluation period and is represented by the vertical white and green bar.
Fig. 5 Example concentration versus time profiles of NPs in blood (left y axis) and tumor (right y axis) and PK metric calculation. The concentration versus time profile in blood is represented by the red symbols and lines. The concentration versus time profile in tumor is represented by the blue symbols and lines. The dotted red and blue lines represent the approximate variability in interquartile range for the blood and tumor concentration versus time profiles, respectively. The dashed gray line represents a constant tumor concentration of 3.5 %ID/g that yields the same AUCtumor (250 hours*%ID/g) as the actual tumor concentration versus time profile. The %ID in tumor calculated by Wilhelm et al. of 0.7% is the average %ID found in the tumor at every 1-hour interval throughout the entire PK evaluation period and is represented by the vertical white and green bar.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 140

Metadata

Authors
Price, L. S. L., Stern, S. T., Deal, A. M., Kabanov, A. V., & Zamboni, W. C.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Corresponding author
Zamboni, William C.
Venue
Science Advances
Published
2020-07-17
Volume
6
Issue
29
Pages
eaay9249-eaay9249
ISSN
2375-2548 (ISSN-L)
OpenAlex
W3042603832
Cited by
128
References
21
Citations by year
2026: 20 · 2025: 14 · 2024: 21 · 2023: 24 · 2022: 19 · 2021: 21 · 2020: 9
FWCI
4.81
Type
journal article
Language
en
Open access
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina - Chapel Hill (1U54CA19899-01 Pilot Grant)
  • Carolina Cancer Nanotechnology Training Program (1T32CA196589, R01CA184088)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Keywords
pharmacokinetics, tumor biodistribution, nanotherapeutics, reanalysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.